# LL-37 and citrullinated-LL-37 enhances oxylipins: citrullination attenuates LL-37-mediated COX-2-dependent chemokine response in human bronchial epithelial cells

**Authors:** Padmanie Ramotar, Mahadevappa Hemshekhar, Anthony Altieri, Anne M van der Does, Christopher D Pascoe, Neeloffer Mookherjee

PMC · DOI: 10.1186/s12931-026-03493-w · 2026-01-14

## TL;DR

This study shows that citrullination of the LL-37 peptide reduces its ability to trigger inflammation in lung cells by affecting lipid and chemokine pathways.

## Contribution

The novel finding is that citrullinated LL-37 attenuates LL-37's pro-inflammatory effects via COX-2-dependent chemokine production in bronchial epithelial cells.

## Key findings

- LL-37 enhances COX-2-dependent oxylipins and chemokine production, which is reduced by citrullination.
- Citrullinated LL-37 does not promote neutrophil migration, unlike non-citrullinated LL-37.
- COX-2-induced PGE2 acts in an autocrine manner to support LL-37-mediated chemokine production.

## Abstract

During airway inflammation, chemokines, oxylipins (bioactive lipids) and cationic host defence peptides (CHDP) are enhanced in the lungs. However, the interplay of these molecules in the process of airway inflammation is not fully resolved. The human cathelicidin CHDP, LL-37, can enhance the expression of chemokines which is turn facilitates influx of leukocytes into the lungs. Moreover, LL-37 can be citrullinated during inflammation and the effect of this post-translational modification on LL-37-mediated immunomodulatory functions remains unclear. Therefore, in this study we aimed to define the impact of LL-37 and citrullinated-LL-37 (citLL-37) on oxylipins and its association with downstream chemokine production in human bronchial epithelial cells (HBEC), and its functional impact on leukocyte influx.

We used a lipidomics approach to identify oxylipins that are enhanced in response to LL-37 and citLL-37 in HBEC. We further examined the role of selected oxylipins in LL-37- and citLL-37-mediated chemokine production by ELISA, and related leukocyte migration using a transwell migration assay.

We showed that LL-37, but not citLL-37, enhances oxylipins that are known to promote inflammation such as prostaglandins regulated by the cyclooxygenase (COX pathway). LL-37-mediated increase in COX-2 expression was significantly higher than that mediated by citLL-37. We showed that upregulation of COX-2 expression was dependent on the P2X7 purinergic receptor. Our mechanistic studies revealed that LL-37-mediated increase in chemokines, GROα, IL-8 and MIP-3α, was dependent on the COX-2 pathway, and that this was significantly attenuated by citrullination of the peptide. Our results also indicated that COX-2-induced PGE2 may act in an autocrine manner signaling through its EP receptors to facilitate LL-37-induced chemokine production. We functionally confirmed that factors secreted from HBEC in response to LL-37, but not citLL-37, promotes neutrophil migration which is COX-2 dependent.

The results of this study indicate that pro-inflammatory responses mediated by LL-37 is attenuated by citrullination of the peptide. The findings of this study underscore the role of LL-37 in influencing the enhancement of bioactive lipids and metabolic pathways such as COX-2 and its link to the peptide-mediated immunomodulatory functions in the lungs.

The online version contains supplementary material available at 10.1186/s12931-026-03493-w.

## Linked entities

- **Genes:** COX2 (cytochrome c oxidase subunit II) [NCBI Gene 4513], P2RX7 (purinergic receptor P2X 7) [NCBI Gene 5027], CXCL1 (C-X-C motif chemokine ligand 1) [NCBI Gene 2919], CXCL8 (C-X-C motif chemokine ligand 8) [NCBI Gene 3576], CCL20 (C-C motif chemokine ligand 20) [NCBI Gene 6364], DBI (diazepam binding inhibitor, acyl-CoA binding protein) [NCBI Gene 1622]
- **Proteins:** CAMP (cathelicidin antimicrobial peptide), COX2 (cytochrome c oxidase subunit II), ptges2.L (prostaglandin E synthase 2 L homeolog)

## Full-text entities

- **Genes:** LOX (lysyl oxidase) [NCBI Gene 4015] {aka AAT10}, P2RX7 (purinergic receptor P2X 7) [NCBI Gene 5027] {aka P2X7}, PTGER1 (prostaglandin E receptor 1) [NCBI Gene 5731] {aka EP1}, PTGER4 (prostaglandin E receptor 4) [NCBI Gene 5734] {aka EP4, EP4R}, CXCL1 (C-X-C motif chemokine ligand 1) [NCBI Gene 2919] {aka FSP, GRO1, GROa, MGSA, MGSA-a, NAP-3}, PTGS1 (prostaglandin-endoperoxide synthase 1) [NCBI Gene 5742] {aka COX1, COX3, PCOX1, PES-1, PGG/HS, PGHS-1}, PTGS2 (prostaglandin-endoperoxide synthase 2) [NCBI Gene 5743] {aka COX-2, COX2, GRIPGHS, PGG/HS, PGHS-2, PHS-2}, COX8A (cytochrome c oxidase subunit 8A) [NCBI Gene 1351] {aka COX, COX8, COX8-2, COX8L, MC4DN15, VIII}, CAMK2G (calcium/calmodulin dependent protein kinase II gamma) [NCBI Gene 818] {aka CAMK, CAMK-II, CAMKG, MRD59}, CXCL8 (C-X-C motif chemokine ligand 8) [NCBI Gene 3576] {aka GCP-1, GCP1, IL8, LECT, LUCT, LYNAP}, PLA2G1B (phospholipase A2 group IB) [NCBI Gene 5319] {aka PLA2, PLA2A, PPLA2}, COX2 (cytochrome c oxidase subunit II) [NCBI Gene 4513] {aka COII, MTCO2}, COX1 (cytochrome c oxidase subunit I) [NCBI Gene 4512] {aka COI, MTCO1}, EGF (epidermal growth factor) [NCBI Gene 1950] {aka HOMG4, URG}, CYP4F3 (cytochrome P450 family 4 subfamily F member 3) [NCBI Gene 4051] {aka CPF3, CYP4F, CYPIVF3, LTB4H}, PTGER2 (prostaglandin E receptor 2) [NCBI Gene 5732] {aka COX-2, EP2}, PPIG (peptidylprolyl isomerase G) [NCBI Gene 9360] {aka CARS-Cyp, CYP, SCAF10, SRCyp}, PTGER3 (prostaglandin E receptor 3) [NCBI Gene 5733] {aka EP3, EP3-I, EP3-II, EP3-III, EP3-IV, EP3-VI}, CCL20 (C-C motif chemokine ligand 20) [NCBI Gene 6364] {aka CKb4, Exodus, LARC, MIP-3-alpha, MIP-3a, MIP3A}, FN1 (fibronectin 1) [NCBI Gene 2335] {aka CIG, ED-B, FINC, FN, FNZ, GFND}, CAMP (cathelicidin antimicrobial peptide) [NCBI Gene 820] {aka CAP-18, CAP18, CRAMP, FALL-39, FALL39, HSD26}
- **Diseases:** Inflammation (MESH:D007249), lung inflammation (MESH:D011014), AMD (MESH:D006009), TC (MESH:D017695), lung cancer (MESH:D008175), Cytotoxicity (MESH:D064420)
- **Chemicals:** EDTA (MESH:D004492), Streptomycin (MESH:D013307), DMSO (MESH:D004121), PUFA (MESH:D005231), Triton X-100 (MESH:D017830), Penicillin (MESH:D010406), ROS (MESH:D017382), arginine (MESH:D001120), Acetic Acid (MESH:D019342), KN62 (MESH:C063302), oxygen (MESH:D010100), Oxylipin (MESH:D054883), PGE1 (MESH:D000527), CO2 (MESH:D002245), 15-HETrE (MESH:C095123), Water (MESH:D014867), citrulline (MESH:D002956), HEPES (MESH:D006531), Arachidonic acid (MESH:D016718), nitrogen (MESH:D009584), lipid (MESH:D008055), PF-04418948 (MESH:C570688), leukotriene (MESH:D015289), PGE2 (MESH:D015232), PGA2 (MESH:C100008), methanol (MESH:D000432), 15-HETE (MESH:C025984), glucose (MESH:D005947), prostaglandin (MESH:D011453), Acetonitrile (MESH:C032159), 11-HETE (MESH:C027356), L-798,106 (-), epoxides (MESH:D004852), EC-23 (MESH:C404934), L-glutamine (MESH:D005973), SC-19220 (MESH:D012531), isoproterenol (MESH:D007545), Rofecoxib (MESH:C116926), MF498 (MESH:C528911)
- **Species:** Homo sapiens (human, species) [taxon 9606]
- **Cell lines:** HBEC — Rattus norvegicus (Rat), Spontaneously immortalized cell line (CVCL_AR51), CRL-4051 — Sigmodon hispidus (Hispid cotton rat), Spontaneously immortalized cell line (CVCL_YD58), -37 — Mus musculus (Mouse), Hybridoma (CVCL_C5J2), sLL-37 — Mus musculus (Mouse), Spontaneously immortalized cell line (CVCL_UR38)

## Figures

7 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12829220/full.md

---
Source: https://tomesphere.com/paper/PMC12829220